VRAX PE Ratio & Valuation, Is VRAX Overvalued

Historical Valuation

Virax Biolabs Group Ltd (VRAX) is now in the Fair zone, suggesting that its current forward PS ratio of 62.82 is considered Fairly compared with the five-year average of -3.16. The fair price of Virax Biolabs Group Ltd (VRAX) is between 0.11 to 0.39 according to relative valuation method.

Relative Value

Fair Zone

0.11-0.39

Current Price：0.20

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Virax Biolabs Group Ltd (VRAX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Virax Biolabs Group Ltd (VRAX) has a current Price-to-Book (P/B) ratio of 0.47. Compared to its 3-year average P/B ratio of 0.74, the current P/B ratio is approximately -35.74% higher. Relative to its 5-year average P/B ratio of 1.99, the current P/B ratio is about -76.22% higher. Virax Biolabs Group Ltd (VRAX) has a Forward Free Cash Flow (FCF) yield of approximately -234.91%. Compared to its 3-year average FCF yield of -160.00%, the current FCF yield is approximately 46.83% lower. Relative to its 5-year average FCF yield of -133.54%, the current FCF yield is about 75.92% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for VRAX competitors is 10.60, providing a benchmark for relative valuation. Virax Biolabs Group Ltd Corp (VRAX.O) exhibits a P/S ratio of 62.82, which is 492.66% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of VRAX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of VRAX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is VRAX currently overvalued or undervalued?

What is Virax Biolabs Group Ltd (VRAX) fair value?

VRAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Virax Biolabs Group Ltd (VRAX) is between 0.11 to 0.39 according to relative valuation method.

How does VRAX's valuation metrics compare to the industry average?

The average P/S ratio for VRAX's competitors is 10.60, providing a benchmark for relative valuation. Virax Biolabs Group Ltd Corp (VRAX) exhibits a P/S ratio of 62.82, which is 492.66% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Virax Biolabs Group Ltd (VRAX) as of Mar 10 2026?

As of Mar 10 2026, Virax Biolabs Group Ltd (VRAX) has a P/B ratio of 0.47. This indicates that the market values VRAX at 0.47 times its book value.

What is the current FCF Yield for Virax Biolabs Group Ltd (VRAX) as of Mar 10 2026?

As of Mar 10 2026, Virax Biolabs Group Ltd (VRAX) has a FCF Yield of -234.91%. This means that for every dollar of Virax Biolabs Group Ltd's market capitalization, the company generates -234.91 cents in free cash flow.

What is the current Forward P/E ratio for Virax Biolabs Group Ltd (VRAX) as of Mar 10 2026?

As of Mar 10 2026, Virax Biolabs Group Ltd (VRAX) has a Forward P/E ratio of -0.38. This means the market is willing to pay $-0.38 for every dollar of Virax Biolabs Group Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Virax Biolabs Group Ltd (VRAX) as of Mar 10 2026?

As of Mar 10 2026, Virax Biolabs Group Ltd (VRAX) has a Forward P/S ratio of 62.82. This means the market is valuing VRAX at $62.82 for every dollar of expected revenue over the next 12 months.

VRAX Valuation